299 related articles for article (PubMed ID: 23673530)
1. Dabigatran: is there a role for coagulation assays in guiding therapy?
Brunetti L; Bandali F
Ann Pharmacother; 2013 Jun; 47(6):828-40. PubMed ID: 23673530
[TBL] [Abstract][Full Text] [Related]
2. Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
Brunetti L; Chen C; White J
Consult Pharm; 2014 Mar; 29(3):169-78. PubMed ID: 24589766
[TBL] [Abstract][Full Text] [Related]
3. Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease.
Bovio JA; Smith SM; Gums JG
Ann Pharmacother; 2011 May; 45(5):603-14. PubMed ID: 21540406
[TBL] [Abstract][Full Text] [Related]
4. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Hawes EM; Deal AM; Funk-Adcock D; Gosselin R; Jeanneret C; Cook AM; Taylor JM; Whinna HC; Winkler AM; Moll S
J Thromb Haemost; 2013 Aug; 11(8):1493-502. PubMed ID: 23718677
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and clinical implications of dabigatran use in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation.
Mack DR; Kim JJ
Ann Pharmacother; 2012; 46(7-8):1105-10. PubMed ID: 22764329
[TBL] [Abstract][Full Text] [Related]
6. Dabigatran for the prevention of thromboembolic complications in the elderly: a RE-LY-able alternative to warfarin?
Hughes PJ; Freeman MK
Consult Pharm; 2012 Jun; 27(6):445-52. PubMed ID: 22698551
[TBL] [Abstract][Full Text] [Related]
7. Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays.
van Ryn J; Grottke O; Spronk H
Clin Lab Med; 2014 Sep; 34(3):479-501. PubMed ID: 25168938
[TBL] [Abstract][Full Text] [Related]
8. Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies.
Fieland D; Taylor M
Ann Pharmacother; 2012 Jan; 46(1):e3. PubMed ID: 22202498
[TBL] [Abstract][Full Text] [Related]
9. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
[TBL] [Abstract][Full Text] [Related]
10. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A
Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
[TBL] [Abstract][Full Text] [Related]
11. [Waiting for the new oral anticoagulants: questions and answers about dabigatran].
Verdecchia P; Agnelli G
G Ital Cardiol (Rome); 2013 Jan; 14(1):35-45. PubMed ID: 23258203
[TBL] [Abstract][Full Text] [Related]
12. [Monitoring of Oral Thrombin Inhibitor].
Matsuno K; Usami T; Hatuse M; Shimizu C
Rinsho Byori; 2014 Oct; 62(10):958-64. PubMed ID: 27526541
[TBL] [Abstract][Full Text] [Related]
13. [Dabigatran, a new oral anticoagulant].
Uchiyama S
Brain Nerve; 2011 Apr; 63(4):411-5. PubMed ID: 21441645
[TBL] [Abstract][Full Text] [Related]
14. Potential inaccuracy of point-of-care INR in dabigatran-treated patients.
Baruch L; Sherman O
Ann Pharmacother; 2011 Jul; 45(7-8):e40. PubMed ID: 21712509
[TBL] [Abstract][Full Text] [Related]
15. Implications of Dabigatran, a direct thrombin inhibitor, for oral surgery practice.
Davis C; Robertson C; Shivakumar S; Lee M
J Can Dent Assoc; 2013; 79():d74. PubMed ID: 23920075
[TBL] [Abstract][Full Text] [Related]
16. Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor.
Augoustides JG
J Cardiothorac Vasc Anesth; 2011 Dec; 25(6):1208-12. PubMed ID: 21982327
[TBL] [Abstract][Full Text] [Related]
17. [Direct oral thrombin inhibitor, "dabigatran"].
Yasaka M
Nihon Rinsho; 2013 Jan; 71(1):113-8. PubMed ID: 23631181
[TBL] [Abstract][Full Text] [Related]
18. The effect of total hip/knee replacement surgery and prophylactic dabigatran on thrombin generation and coagulation parameters.
Green L; Lawrie AS; Patel R; Stephens RC; Mackie IJ; Chitolie A; Haddad FS; Machin SJ
Thromb Res; 2012 Nov; 130(5):775-9. PubMed ID: 22245224
[TBL] [Abstract][Full Text] [Related]
19. Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies.
Garwood CL; Hwang JM; Moser LR
Pharmacotherapy; 2011 Dec; 31(12):1208-20. PubMed ID: 22122182
[TBL] [Abstract][Full Text] [Related]
20. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
Hapgood G; Butler J; Malan E; Chunilal S; Tran H
Thromb Haemost; 2013 Aug; 110(2):308-15. PubMed ID: 23783268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]